June 2017 Vol 10, No 4
Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas
Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes
Kelvin Lingjet Tran, DO, Young In Park, DO, Shalin Pandya, DO, Navin John Muliyil, DO, Brandon David Jensen, DO, Kovin Huynh, DO, Quang T. Nguyen, DO, FACP, FACE, FTOS
It is estimated that 29.1 million people or 9.3% of the US population have diabetes, which contributes to considerable medical and financial burden.
The GLP-1 Receptor Agonists Are Cost-Effective for the Treatment of Type 2 Diabetes
Hyperkalemia, which is defined as an elevated serum potassium level (ie, >5.0 mEq/L), may be caused by a reduction in the renal excretion of potassium or an intracellular-to-extracellular shift in potassium that results from various acute clinical conditions. Although the kidney can adjust to a reduced number of nephrons and maintain normokalemia under steady-state conditions, it lacks the ability to respond to acute increases in potassium load and to adequately excrete potassium in patients with chronic kidney disease (CKD); the result in both cases is hyperkalemia.
Hyperkalemia in Chronic Diseases: A Serious Medical Condition in Need of Clinical Guidelines and New Treatment Options
Results 1 - 5 of 5